4d pharma plc's (LON:DDDD) Duncan Peyton updates Proactive's Andrew Scott following the news the next stage of its cancer clinical study is underway with four new sites added in the US to accelerate patient recruitment. Up to 30 people per tumour type will participate in Part B of the company’s phase I/II trial to assess its live biotherapeutic, MRx0518, in combination with immune checkpoint inhibitor Keytruda.
view4D pharma PLC
4d pharma's Duncan Peyton outlines crucial next stage for its cancer trial
Quick facts: 4D pharma PLC
Price: 122 GBX
LSE:DDDD
Market: LSE
Market Cap: £160.3 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of 4D pharma PLC named herein, including the promotion by the Company of 4D pharma PLC in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
4D pharma: A clinical stage innovator and pioneer of Live Biotherapeutics
Most read
Industry & services
New space ETF on the horizon lifts shares in Virgin Galactic, Maxar and SRAC
2 days, 2 hours ago
Finance
Today's Market View - Arc Minerals; Ariana Resources; BlueRock Diamonds;...
4 days, 5 hours ago
Finance
Bitcoin price plunges as FCA warns crypto investors could lose all their money
5 days, 1 hour ago
Finance
Today's Market View - Arc Minerals; Ariana Resources; BlueRock Diamonds;...
4 days, 4 hours ago
